This article is from the source 'bbc' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at http://www.bbc.co.uk/go/rss/int/news/-/news/business-13451734
The article has changed 2 times. There is an RSS feed of changes available.
Previous version
1
Next version
Version 0 | Version 1 |
---|---|
Japan's Takeda to buy Swiss drugmaker Nycomed | Japan's Takeda to buy Swiss drugmaker Nycomed |
(about 2 hours later) | |
Japan's largest drugmaker Takeda Pharmaceutical has agreed to buy Swiss rival Nycomed for 9.6bn euros ($13.7bn; £8.5bn). | |
The acquisition will give Takeda access to Nycomed's new lung drug, which was approved for use in the US in March. | The acquisition will give Takeda access to Nycomed's new lung drug, which was approved for use in the US in March. |
It is Takeda's second major overseas deal. The company bought US cancer specialist Millennium Pharmaceuticals for $8.8bn in 2008. | It is Takeda's second major overseas deal. The company bought US cancer specialist Millennium Pharmaceuticals for $8.8bn in 2008. |
Nycomed is currently majority-owned by four private equity companies. | Nycomed is currently majority-owned by four private equity companies. |
Nordic Capital owns 41% of Nycomed, DLJ Merchant Banking holds 25.6%, Coller International Partners has 9.7% and Avista owns 8.9%. | Nordic Capital owns 41% of Nycomed, DLJ Merchant Banking holds 25.6%, Coller International Partners has 9.7% and Avista owns 8.9%. |
The lung drug roflumilast, which is known as Daxas in Europe and Daliresp in the US, is a new class of treatment for chronic pulmonary disease, a breathing disorder caused by smoking. | The lung drug roflumilast, which is known as Daxas in Europe and Daliresp in the US, is a new class of treatment for chronic pulmonary disease, a breathing disorder caused by smoking. |
Yasuchika Hasegawa, chief executive of Takeda, said: "Nycomed enables Takeda to maximise the value of our portfolio and gives us an immediate strong presence in the high-growth emerging markets while doubling Takeda's European sales." | Yasuchika Hasegawa, chief executive of Takeda, said: "Nycomed enables Takeda to maximise the value of our portfolio and gives us an immediate strong presence in the high-growth emerging markets while doubling Takeda's European sales." |
Previous version
1
Next version